Skip to main content
OpenTrials
Completed

NCT Number: NCT02682524

Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee

A multicenter, randomized, double-blinded, parallel, active-controlled, phase IV clinical trial to evaluate the efficacy and safety of PlbCR and aceclofenac in the treatment of patients with osteoarthritis of the knee

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Inha university hospital

Chung Gu, Incheon, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • both male and female who is over 35year-old and below 80year-old
  • patient who diagnosed as Kellgren & Lawrence stage I~III by X-ray
  • osteoarthritis patient who is stable within 3months form starting this clinical trial
  • patient who is over 40mm in 100mm Pain VAS at Visit 2
  • patient who agreed to participate this clinical trial spontaneously

Exclusion criteria

  • second osteoarthritis
  • patient who has inflammatory disease which can effect efficacy outcomes such as bursitis, tenosynovitis, rheumatoid arthritis, etc.
  • patient who diagnosed as gastric ulcer or GI disease by esophagogastroduodenoscopy
  • patient who had joint surgery within 12months form screening visit of this clinical trial or planned to operate in this clinical trial period
  • patient who has had artificial joint surgery of knee
  • malignant tumor patient
  • patient who has taken Psychopharmaceutical or Narcotic Analgesics over 3months continuously
  • patient who took steroid by oral, inhalation or intraarticular injection within 3months form screening visit of this clinical trial
  • patient who took intraarticular hyaluronic acid injection of knee within 2months form screening visit of this clinical trial
  • patient who cannot take NSAIDs because of disease or medicine
  • allergy of aspirin of other NSAIDs
  • patient who has to handle his/her pain by or for CABG
  • galactose intolerance, Lactose Intolerance or glucose-galactose malabsorption
  • inflammatory bowel disease such as ulcerative colitis or Crohn's disease
  • moderate renal disease
  • moderate hepatic disease
  • moderate hypertension(SBP=>160mmHg, DBP=>100mmHg)
  • female who consents to contracept
  • patient who is not appropriate for this clinical trial

Treatment and study plan

Pelubiprofen CR 45mg tab.

Drug

Aceclofenac 100mg tab.

Drug

Primary outcomes

  1. Change from baseline 100mm Pain VAS at 4weeks

    Time frame: 4weeks

Secondary outcomes

  1. Change from baseline 100mm Pain VAS at 2weeks

    Time frame: 2weeks

  2. Change from baseline K-WOMAC Scale at 2weeks and 4weeks

    Time frame: 2weeks, 4weeks

  3. Patient Global Assessment

    Time frame: 4weeks

Sponsors and collaborators

Lead sponsor

Daewon Pharmaceutical Co., Ltd.

Industry

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Feb 15, 2016
Registry last updated
Oct 10, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.